NIBRT Publish Annual Report 2025
NIBRT Announces Record Growth Across Training, Research and Global Engagement in 2025
Dublin, Ireland, 26th February 2026: NIBRT has today released its Annual Report 2025, detailing a year of record growth, expanded capability and strengthened global engagement across the biopharmaceutical sector. Against the backdrop of a rapidly evolving international biopharma landscape, NIBRT delivered substantial progress in 2025, contributing to Ireland’s continued strength as a global hub for biopharmaceutical manufacturing.
Commenting on the Annual Report, NIBRT Chairperson Julie O’Neill remarked, “2025 was a further year of strong performance for NIBRT. The achievements outlined in this report reflect the Institute’s ability to deliver consistently high-quality training, impactful research and strong governance amid a changing global environment.”
Highlights from the year included:
Expanding Research Excellence and Strengthening Capability
• NIBRT has secured €28.6 million in new research funding between 2023 and 2025
• Establishment of the Metabolomics Discovery Lab, Ireland’s first high throughput national metabolomics platform
• Continued development of the CONCEPT facility supporting cell, gene and RNA therapeutic development
• Strengthened European leadership through participation in Horizon Europe consortia strategic networks and hosting the research conference “Ireland’s Role in Europe’s Biotech Future”
World Class Training with Global Reach
• Training delivered to 4,900 people with an average satisfaction score of 91%
• Launch of NIBRT Global Qualifications (NGQs), establishing a new internationally recognised skills standard
• Growing reach of the NIBRT Online Academy, now used in 97 countries
• Development of expanded training content
• Expansion of the Global Partner Programme, with Heartland BioWorks (Indiana, USA) joining as the newest member
ESG, People and Organisational Excellence
NIBRT also delivered strong progress across environmental, social and governance priorities, achieving a 53% reduction in CO₂ emissions since 2017, earning the Investors in Diversity Silver Award, recruiting 31 new employees, and maintaining high staff engagement, with 80% of employees agreeing NIBRT is a great place to work.
Dr Darrin Morrissey, CEO of NIBRT, added: “Our progress this year is a testament to the dedication of the NIBRT team and the strength of our partnerships across industry, academia and government. We are well positioned to meet the growing global demand for skilled talent and applied bioprocessing research to support the continued development of the biopharma sector in Ireland.”
DOWNLOAD ANNUAL REPORT
**End of press release**
About NIBRT
The National Institute for Bioprocessing Research and Training (NIBRT) is a global centre of excellence for training and research in biopharmaceutical manufacturing. NIBRT is located in a world-class facility in Dublin, Ireland. This facility is purpose built to closely replicate a modern bioprocessing plant with state-of-the-art equipment and enables NIBRT to offer high quality training and research solutions. NIBRT’s mission is to support the growth and development of all aspects of the biopharmaceutical manufacturing industry. For more information, please visit www.nibrt.ie.
Media Contacts:
Name: Emer Norton
Title: NIBRT Marketing and Communications Manager
Email: emer.norton@nibrt.ie
Phone: +353 1 215 8100
